8WTW image
Entry Detail
PDB ID:
8WTW
EMDB ID:
Title:
Cryo-EM structure of noradrenaline transporter in complex with a x-MrlA analogue
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2023-10-19
Release Date:
2024-08-07
Method Details:
Experimental Method:
Resolution:
2.80 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Sodium-dependent noradrenaline transporter
Chain IDs:A
Chain Length:566
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:MrlA
Chain IDs:B
Chain Length:15
Number of Molecules:1
Biological Source:Conus marmoreus
Primary Citation
Transport and inhibition mechanisms of the human noradrenaline transporter.
Nature 632 930 937 (2024)
PMID: 39085602 DOI: 10.1038/s41586-024-07638-z

Abstact

The noradrenaline transporter (also known as norepinephrine transporter) (NET) has a critical role in terminating noradrenergic transmission by utilizing sodium and chloride gradients to drive the reuptake of noradrenaline (also known as norepinephrine) into presynaptic neurons1-3. It is a pharmacological target for various antidepressants and analgesic drugs4,5. Despite decades of research, its structure and the molecular mechanisms underpinning noradrenaline transport, coupling to ion gradients and non-competitive inhibition remain unknown. Here we present high-resolution complex structures of NET in two fundamental conformations: in the apo state, and bound to the substrate noradrenaline, an analogue of the χ-conotoxin MrlA (χ-MrlAEM), bupropion or ziprasidone. The noradrenaline-bound structure clearly demonstrates the binding modes of noradrenaline. The coordination of Na+ and Cl- undergoes notable alterations during conformational changes. Analysis of the structure of NET bound to χ-MrlAEM provides insight into how conotoxin binds allosterically and inhibits NET. Additionally, bupropion and ziprasidone stabilize NET in its inward-facing state, but they have distinct binding pockets. These structures define the mechanisms governing neurotransmitter transport and non-competitive inhibition in NET, providing a blueprint for future drug design.

Legend

Protein

Chemical

Disease

Primary Citation of related structures